Circulating tumour DNA in patients with advanced melanoma treated with dabrafenib or dabrafenib plus trametinib: a clinical validation study

达布拉芬尼 曲美替尼 医学 肿瘤科 黑色素瘤 癌症研究 转移性黑色素瘤 威罗菲尼 MAPK/ERK通路 遗传学 磷酸化 生物
作者
Mahrukh M. Syeda,Jennifer Wiggins,Broderick C. Corless,Georgina V. Long,Keith T. Flaherty,Dirk Schadendorf,Paul Nathan,Caroline Robert,Antoni Ribas,Michael A. Davies,Jean‐Jacques Grob,Eduard Gasal,Matthew Squires,Mahtab Marker,James E. Garrett,Jan C. Brase,David Polsky
出处
期刊:Lancet Oncology [Elsevier BV]
卷期号:22 (3): 370-380 被引量:94
标识
DOI:10.1016/s1470-2045(20)30726-9
摘要

Background Melanoma lacks validated blood-based biomarkers for monitoring and predicting treatment efficacy. Cell-free circulating tumour DNA (ctDNA) is a promising biomarker; however, various detection methods have been used, and, to date, no large studies have examined the association between serial changes in ctDNA and survival after BRAF, MEK, or BRAF plus MEK inhibitor therapy. We aimed to evaluate whether baseline ctDNA concentrations and kinetics could predict survival outcomes. Methods In this clinical validation study, we used analytically validated droplet digital PCR assays to measure BRAFV600-mutant ctDNA in pretreatment and on-treatment plasma samples from patients aged 18 years or older enrolled in two clinical trials. COMBI-d (NCT01584648) was a double-blind, randomised phase 3 study of dabrafenib plus trametinib versus dabrafenib plus placebo in previously untreated patients with BRAFV600 mutation-positive unresectable or metastatic melanoma. Patients had an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. COMBI-MB (NCT02039947) was an open-label, non-randomised, phase 2 study evaluating dabrafenib plus trametinib in patients with BRAFV600 mutation-positive metastatic melanoma and brain metastases. Patients in cohort A of COMBI-MB had asymptomatic brain metastases, no previous local brain-directed therapy, and an ECOG performance status of 0 or 1. Biomarker analysis was a prespecified exploratory endpoint in both trials and performed in the intention-to-treat populations in COMBI-d and COMBI-MB. We investigated the association between mutant copy number (baseline or week 4 or zero conversion status) and efficacy endpoints (progression-free survival, overall survival, and best overall response). We used Cox models, Kaplan-Meier plots, and log-rank tests to explore the association of pretreatment ctDNA concentrations with progression-free survival and overall survival. The effect of additional prognostic variables such as lactate dehydrogenase was also investigated in addition to the mutant copy number. Findings In COMBI-d, pretreatment plasma samples were available from 345 (82%) of 423 patients and on-treatment (week 4) plasma samples were available from 224 (53%) of 423 patients. In cohort A of COMBI-MB, pretreatment and on-treatment samples were available from 38 (50%) of 76 patients with intracranial and extracranial metastatic melanoma. ctDNA was detected in pretreatment samples from 320 (93%) of 345 patients (COMBI-d) and 34 (89%) of 38 patients (COMBI-MB). When assessed as a continuous variable, elevated baseline BRAFV600 mutation-positive ctDNA concentration was associated with worse overall survival outcome (hazard ratio [HR] 1·13 [95% CI 1·09–1·18], p<0·0001 by univariate analysis), independent of treatment group and baseline lactate dehydrogenase concentrations (1·08 [1·03–1·13], p=0·0020), in COMBI-d. A ctDNA cutoff point of 64 copies per mL of plasma stratified patients enrolled in COMBI-d as high risk or low risk with respect to survival outcomes (HR 1·74 [95% CI 1·37–2·21], p<0·0001 for progression-free survival; 2·23 [1·73–2·87], p<0·0001 for overall survival) and was validated in the COMBI-MB cohort (3·20 [1·39–7·34], p=0·0047 for progression-free survival; 2·94 [1·18–7·32], p=0·016 for overall survival). In COMBI-d, undetectable ctDNA at week 4 was significantly associated with extended progression-free and overall survival, particularly in patients with elevated lactate dehydrogenase concentrations (HR 1·99 [95% CI 1·08–3·64], p=0·027 for progression-free survival; 2·38 [1·24–4·54], p=0·0089 for overall survival). Interpretation Pretreatment and on-treatment BRAFV600-mutant ctDNA measurements could serve as independent, predictive biomarkers of clinical outcome with targeted therapy. Funding Novartis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
灰灰完成签到 ,获得积分10
刚刚
刚刚
clement完成签到,获得积分10
1秒前
林中鸟完成签到,获得积分10
1秒前
1秒前
ding的应助被一颗椰子糖耶采纳,获得10
2秒前
星星完成签到,获得积分10
2秒前
2秒前
细腻的歌曲完成签到,获得积分10
2秒前
3秒前
鬼先生发布了新的文献求助10
4秒前
ZCF_Timme完成签到,获得积分10
4秒前
4秒前
Mint完成签到,获得积分10
4秒前
4秒前
六花完成签到,获得积分10
4秒前
莓莓发布了新的文献求助10
5秒前
刘大宝发布了新的文献求助10
5秒前
萌~Lucky完成签到,获得积分10
6秒前
7秒前
科研通AI6.3的应助被鬼先生采纳,获得10
7秒前
初景的应助被geold采纳,获得20
8秒前
汉堡包的应助被stanfordlee采纳,获得10
9秒前
kuku发布了新的文献求助10
9秒前
王悦靓发布了新的文献求助10
9秒前
无私尔风完成签到,获得积分10
9秒前
平静的人完成签到 ,获得积分10
9秒前
孙大伟完成签到,获得积分20
9秒前
吾吾发布了新的文献求助10
9秒前
10秒前
10秒前
mm完成签到,获得积分10
10秒前
popooo完成签到,获得积分10
10秒前
stayu完成签到 ,获得积分10
10秒前
糖醋花孙米完成签到,获得积分10
10秒前
科研通AI2S的应助被lihao采纳,获得10
11秒前
2000皁空完成签到,获得积分10
11秒前
小连完成签到,获得积分10
11秒前
厉奕欣发布了新的文献求助10
11秒前
12秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8180757
求助须知:如何正确求助?哪些是违规求助? 9570857
关于积分的说明 21814590
捐赠科研通 7777053
什么是DOI,文献DOI怎么找? 3433314
关于科研通互助平台的介绍 2557579
邀请新用户注册赠送积分活动 2479315